Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer's ...

Therefore, anti-glycemic drugs could potentially have neuroprotective effects in type 2 diabetes patients ... populations and in specific dementia types has not been studied. In the present cohort ...

Scientists say they have achieved a "first" in the development of drugs to treat Alzheimer's disease. In a study published in the journal Alzheimer's & Dementia, a team of researchers report the ...

Variations in the use of antidementia and antipsychotic drugs for nursing home residents with dementia across the United ...

The use of SGLT2 inhibitors vs DDP-4 inhibitors is associated with a reduced risk of developing different types of dementia.

In a study led by the Johns Hopkins University School of Medicine and Tufts University School of Medicine, researchers show ...

A new study, however by the universities of Manchester, Nottingham, Edinburgh and Dundee, published in the BMJ, has found that antipsychotic drugs prescribed to dementia patients cause more ... light ...

Among the adverse effects reported in the trial, infusion-related reactions were observed in 26.4% of patients in the ...

The European Medicines Agency’s human medicines committee is re-examining the marketing authorisation application for the ...

The findings were particularly pronounced in individuals with dementia, pointing to a possible vascular benefit of higher BP.

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

SGLT2 inhibitors and dulaglutide are associated with comparable risk for dementia; however, it is uncertain whether these findings generalize to newer GLP-1 RAs.